News | Ventricular Assist Devices (VAD) | July 09, 2015

Abiomed Announces Expansion of U.S. Headquarters

Maker of the Impella heart pumps expected to bring 100 new local jobs

Abiomed, U.S. headquarters expansion, Impella 2.5, RP, jobs

July 9, 2015 - During an event with Massachusetts Gov. Charlie Baker in June, Abiomed announced a major expansion of its U.S. headquarters in Danvers, Massachusetts, and the creation of approximately 100 new, local jobs.

Abiomed will lease an additional 85,000 square feet of space in a building adjacent to its current U.S. headquarters in Danvers. The added space will be dedicated to manufacturing and research.

The company currently has more than 600 employees, nearly half of which work in Massachusetts. Over the past two years, Abiomed has already added 150 jobs in the Commonwealth.

Duane Pinto, M.D., a cardiologist and director of the cardiac intensive care unit at Beth Israel Deaconess Medical Center, also attended the event at Abiomed's Danvers headquarters.

Plans for Abiomed's U.S. expansion follow two recent U.S. Food and Drug (FDA) approvals of its heart pump devices. Most recently, in March, Abiomed received a FDA Pre-Market Approval (PMA) for the Impella 2.5 heart pump to be using during elective and urgent high-risk percutaneous coronary intervention (PCI) procedures.

As many as 100,000 U.S. cardiac patients are turned down for heart surgery each year because the risks are too high, and the Impella 2.5 is approved for use to help patients maintain stable heart function and circulation during certain high-risk procedures.

In January, Abiomed's Impella RP (Right Percutaneous) System received FDA approval under a Humanitarian Device Exemption (HDE). The Impella RP is a single access right-sided percutaneous ventricular assist device and is FDA indicated for providing circulatory assistance to pediatric or adult patients who develop acute right heart failure or decompensation for up to 14 days.

For more information: www.abiomed.com


Related Content

News | Ventricular Assist Devices (VAD)

June 19, 2024 — When electrophysiologist Eugenio Cingolani, MD, isn’t seeing patients, he can usually be found in his ...

Home June 19, 2024
Home
News | Ventricular Assist Devices (VAD)

October 31, 2023 — Tenaya Therapeutics, Inc., a clinical-stage biotechnology company with a mission to discover, develop ...

Home October 31, 2023
Home
News | Ventricular Assist Devices (VAD)

June 7, 2023 — Magenta Medical Ltd. has announced the initiation of its FDA-approved Early Feasibility Study with the ...

Home June 07, 2023
Home
News | Ventricular Assist Devices (VAD)

March 1, 2023 — Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, today ...

Home March 01, 2023
Home
News | Ventricular Assist Devices (VAD)

November 2, 2022 — For decades, left ventricular-assist devices (LVADs) have extended the lives of people whose hearts ...

Home November 02, 2022
Home
News | Ventricular Assist Devices (VAD)

October 18, 2022 — The U.S. Food and Drug Administration (FDA) is providing updates to the FDA website to include ...

Home October 18, 2022
Home
News | Ventricular Assist Devices (VAD)

August 25, 2022 — The U.S. Food and Drug Administration (FDA) issued a statement that Medtronic, Inc. is recalling ...

Home August 25, 2022
Home
News | Ventricular Assist Devices (VAD)

August 5, 2022 — Black people and women with severe heart failure who might be good candidates for surgery to implant a ...

Home August 05, 2022
Home
News | Ventricular Assist Devices (VAD)

June 23, 2022 — Medtronic, Inc. is recalling a single lot of HeartWare HVAD System batteries due to welding defects that ...

Home June 23, 2022
Home
News | Ventricular Assist Devices (VAD)

June 8, 2022 — The U.S. Food and Drug Administration (FDA) has issued a release stating that Medtronic is recalling the ...

Home June 08, 2022
Home
Subscribe Now